Lentigen

Since just June, 2005, when Lentigen first opened its doors, it has perfected and productized an optimized, safe and effective lentiviral vector and used it to accomplish the following:

1. Create a vaccine for the H5N1 (bird flu) Influenza virus using cell-based viral like particles (VLP). The vaccine can be rapidly manufactured resulting in a vaccine that is exactly derived from the pandemic influenza viral strain. The VLP is genetically inactive, avoiding the current need for chemical inactivation. The high potency of the influenza VLPs will dramatically reduce their cost and therefore make them more widely available. Lentigen has demonstrated successful immune responses for the vaccine in lab animals. This patent applied approach can be applied to make any vaccines rapidly, efficiently and cost effectively.

Consequently, Lentigen's approach eliminates the dependency on the fact that there are not enough eggs in the world to produce vaccine for a bird flu pandemic. Furthermore, if and when a bird flu mutates to be transferable between humans, it is highly likely that it will greatly reduce the world's poultry population, and hence, our ability to have enough eggs for vaccines.

2. Create a new method to produce a biogeneric versions of current biologics. For example, Epogen has annual sales of $11.4B and many of the patents covering the protein are coming to term. This same novel patent applied technique that Lentigen used for developing erythropoietin can be used for the development of any biologic such as other proteins and monoclonal antibodies.

3. Sign deals for providing LV for the clinical trials for a wide variety of therapies, including Parkinson's Disease, leukemia, and lymphoma, among others to be announced.

4. Sign a major distribution deal with Fisher Scientific's Dharmacon for development of new generation Lentiviral based RNAi products.

5. Sign a CRADA (collaborative research and development agreement) with the US Army's Edgewood Chemical Biological Center to focus on vaccines, therapeutics and biodefense.

6. Secure the market rights to gene therapies for leukemia, two forms of lymphoma, and graft versus host diseases (GVHD), among others.

7. Sign a collaborative research agreement with the University of Pennsylvania for the development of novel cancer therapies.

8. Gain recognition as one of the Top 100 early stage companies in North America by Red Herring magazine.

http://www.lentigen.com/